brigatinib and its Impurities

Brigatinib acts as both an anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. It is a small molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.. Reference standards of Brigatinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below